Delving into the Latest Updates on Patheon France SAS with Synapse

Overview

Tags

Congenital Disorders

Digestive System Disorders

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

ISBT(Ileal bile acid transporter)	1

主要目的：比较nemtabrutinib与伊布替尼或阿可替尼由BICR根据2018年iwCLL标准评估的ORR；比较nemtabrutinib与伊布替尼或阿可替尼由BICR根据2018年iwCLL标准评估的PFS。次要目的：比较nemtabrutinib与伊布替尼或阿可替尼的OS；评价由BICR根据2018年iwCLL标准评估的DOR；评价nemtabrutinib的安全性和耐受性。

[Translation]

Primary objectives: Compare the ORR of nemtabrutinib with ibrutinib or acomatinib as assessed by BICR according to the 2018 iwCLL criteria; Compare the PFS of nemtabrutinib with ibrutinib or acomatinib as assessed by BICR according to the 2018 iwCLL criteria. Secondary objectives: Compare the OS of nemtabrutinib with ibrutinib or acomatinib; Evaluate the DOR assessed by BICR according to the 2018 iwCLL criteria; Evaluate the safety and tolerability of nemtabrutinib.

Start Date20 May 2024

Sponsor / Collaborator

Catalent CTS LLC

[+3]

CTR20233090 / RecruitingPhase 3

一项评价Odevixibat（A4250）在胆管闭锁儿童中的长期疗效和安全性的开放性扩展研究（BOLD-EXT）

[Translation] An open-label extension study evaluating the long-term efficacy and safety of odevixibat (A4250) in children with biliary atresia (BOLD-EXT)

主要目的：证明Odevixibat对已完成研究A4250-011（BOLD）的胆管闭锁（BA）儿童自体肝存活率的持续影响

[Translation]

Primary Objective: To demonstrate the sustained effect of odevixibat on native liver survival in children with biliary atresia (BA) who have completed Study A4250-011 (BOLD)

Start Date01 Mar 2024

Sponsor / Collaborator

Syneos Health (Beijing) Inc.Ltd.

[+2]

CTR20230821 / RecruitingPhase 3

一项在既往未经治疗的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者（无TP53畸变）中比较MK-1026与化学免疫疗法的有效性和安全性的III期、随机研究（BELLWAVE-008）

[Translation] A Phase III, randomized study comparing the efficacy and safety of MK-1026 with chemoimmunotherapy in patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma without TP53 aberrations (BELLWAVE-008)

主要目的：比较MK-1026与研究者选择的化学免疫治疗（氟达拉滨+环磷酰胺+利妥昔单抗[FCR]或苯达莫司汀+利妥昔单抗[BR]）的PFS；次要目的：在OS、ORR和DOR方面，比较MK-1026与研究者选择的化学免疫治疗（FCR或BR）；评价MK-1026的安全性和耐受性。

[Translation]

Primary objective: To compare the PFS of MK-1026 with that of investigator's choice of chemoimmunotherapy (fludarabine + cyclophosphamide + rituximab [FCR] or bendamustine + rituximab [BR]); Secondary objectives: To compare MK-1026 with that of investigator's choice of chemoimmunotherapy (FCR or BR) in terms of OS, ORR and DOR; To evaluate the safety and tolerability of MK-1026.

Start Date06 Jul 2023

Sponsor / Collaborator

Catalent CTS LLC

[+3]

100 Clinical Results associated with Patheon France SAS

Login to view more data

0 Patents (Medical) associated with Patheon France SAS

Login to view more data

100 Deals associated with Patheon France SAS

Login to view more data

100 Translational Medicine associated with Patheon France SAS

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

NDA/BLA

1

Login to view more data